Estrogens and SERMS as adjunctive treatments for schizophrenia

Jayashri Kulkarni, Surina Butler, Anita Riecher-Rössler

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

More than thirty years have passed since sex and gender differences were noted in the age of onset, course and outcomes for schizophrenia. The ‘estrogen hypothesis” was coined in the 1990′s to describe neuroprotective effects of estrogen. Intervention studies in schizophrenia patients with estradiol and selective estrogen receptor modulators (SERMs) are promising but psychiatrists and other health practitioners do not generally take up this useful adjunctive treatment for their female patients with schizophrenia. The reasons for this are manifold, but overall a cultural shift in the practice of psychiatry is needed to recognise the specific needs of women with schizophrenia and tailor treatments, such as hormone adjuncts to improve the outcomes for this significant population. The two main aims of this article are to review the evidence and theory of estrogen treatments in schizophrenia and to recommend translation of adjunctive estrogen treatment into clinical practice for women with schizophrenia.

Original languageEnglish
Article number100743
Number of pages8
JournalFrontiers in Neuroendocrinology
Volume53
DOIs
Publication statusPublished - 1 Apr 2019

Keywords

  • Estrogens
  • Schizophrenia
  • SERMs
  • Sex
  • Women

Cite this

@article{262b94cbbbb7448d997b3ce6ee03f71a,
title = "Estrogens and SERMS as adjunctive treatments for schizophrenia",
abstract = "More than thirty years have passed since sex and gender differences were noted in the age of onset, course and outcomes for schizophrenia. The ‘estrogen hypothesis” was coined in the 1990′s to describe neuroprotective effects of estrogen. Intervention studies in schizophrenia patients with estradiol and selective estrogen receptor modulators (SERMs) are promising but psychiatrists and other health practitioners do not generally take up this useful adjunctive treatment for their female patients with schizophrenia. The reasons for this are manifold, but overall a cultural shift in the practice of psychiatry is needed to recognise the specific needs of women with schizophrenia and tailor treatments, such as hormone adjuncts to improve the outcomes for this significant population. The two main aims of this article are to review the evidence and theory of estrogen treatments in schizophrenia and to recommend translation of adjunctive estrogen treatment into clinical practice for women with schizophrenia.",
keywords = "Estrogens, Schizophrenia, SERMs, Sex, Women",
author = "Jayashri Kulkarni and Surina Butler and Anita Riecher-R{\"o}ssler",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.yfrne.2019.03.002",
language = "English",
volume = "53",
journal = "Frontiers in Neuroendocrinology",
issn = "0091-3022",
publisher = "Elsevier",

}

Estrogens and SERMS as adjunctive treatments for schizophrenia. / Kulkarni, Jayashri; Butler, Surina; Riecher-Rössler, Anita.

In: Frontiers in Neuroendocrinology, Vol. 53, 100743, 01.04.2019.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Estrogens and SERMS as adjunctive treatments for schizophrenia

AU - Kulkarni, Jayashri

AU - Butler, Surina

AU - Riecher-Rössler, Anita

PY - 2019/4/1

Y1 - 2019/4/1

N2 - More than thirty years have passed since sex and gender differences were noted in the age of onset, course and outcomes for schizophrenia. The ‘estrogen hypothesis” was coined in the 1990′s to describe neuroprotective effects of estrogen. Intervention studies in schizophrenia patients with estradiol and selective estrogen receptor modulators (SERMs) are promising but psychiatrists and other health practitioners do not generally take up this useful adjunctive treatment for their female patients with schizophrenia. The reasons for this are manifold, but overall a cultural shift in the practice of psychiatry is needed to recognise the specific needs of women with schizophrenia and tailor treatments, such as hormone adjuncts to improve the outcomes for this significant population. The two main aims of this article are to review the evidence and theory of estrogen treatments in schizophrenia and to recommend translation of adjunctive estrogen treatment into clinical practice for women with schizophrenia.

AB - More than thirty years have passed since sex and gender differences were noted in the age of onset, course and outcomes for schizophrenia. The ‘estrogen hypothesis” was coined in the 1990′s to describe neuroprotective effects of estrogen. Intervention studies in schizophrenia patients with estradiol and selective estrogen receptor modulators (SERMs) are promising but psychiatrists and other health practitioners do not generally take up this useful adjunctive treatment for their female patients with schizophrenia. The reasons for this are manifold, but overall a cultural shift in the practice of psychiatry is needed to recognise the specific needs of women with schizophrenia and tailor treatments, such as hormone adjuncts to improve the outcomes for this significant population. The two main aims of this article are to review the evidence and theory of estrogen treatments in schizophrenia and to recommend translation of adjunctive estrogen treatment into clinical practice for women with schizophrenia.

KW - Estrogens

KW - Schizophrenia

KW - SERMs

KW - Sex

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85063383982&partnerID=8YFLogxK

U2 - 10.1016/j.yfrne.2019.03.002

DO - 10.1016/j.yfrne.2019.03.002

M3 - Review Article

VL - 53

JO - Frontiers in Neuroendocrinology

JF - Frontiers in Neuroendocrinology

SN - 0091-3022

M1 - 100743

ER -